Red blood cells contain a pathway for the degradation of oxidant-damaged hemoglobin that does not require ATP or ubiquitin.
It is generally accepted that ATP is required for intracellular protein breakdown. Reticulocytes contain a soluble ATP-dependent pathway for the degradation of highly abnormal proteins and for the elimination of certain proteins during cell maturation. Reticulocytes and erythrocytes also selectively degrade proteins damaged by oxidation. When these cells were exposed to oxidants, such as phenylhydrazine or nitrite, they showed a large increase in protein breakdown. This oxidant-induced proteolysis was not inhibited in cells depleted of ATP. However, ATP depletion did prevent the degradation of pre-existent cell proteins. In reticulocyte extracts, phenylhydrazine-treated hemoglobin is also degraded rapidly by an ATP-independent process, unlike endogenous proteins and many exogenous polypeptides. This lack of an ATP requirement means that the degradation of oxidant-damaged proteins does not require ligation to ubiquitin (even though phenylhydrazine treatment does make hemoglobin a very good substrate for ubiquitin conjugation). In many respects, the pathway for breakdown of oxidant-treated hemoglobin differs from the ATP-dependent process. The latter has a much higher activation energy than the degradation of oxidized proteins. The ATP-dependent process is inhibited by hemin, 3,4-dichloroisocoumarin, diisopropylfluorophosphate and N-ethylmaleimide. The ATP-independent pathway is less sensitive to N-ethylmaleimide, hemin, and 3,4-dichloroisocoumarin and is not affected by diisopropylfluorophosphate. In addition, only the ATP-dependent proteolytic process is inactivated by dilution or incubation at 37 degrees C in the absence of nucleotides. Reticulocytes thus contain multiple soluble systems for degrading proteins and can rapidly hydrolyze certain types of abnormal proteins by either an ATP-independent or ATP-dependent process. Erythrocytes lack the ATP-dependent process present in reticulocytes; however, erythrocytes retain the capacity to degrade oxidant-damaged hemoglobin. These two processes probably are active in the elimination of different types of abnormal proteins.
D019297:2,4-Dinitrophenol; D000255:Adenosine Triphosphate / Q000097:blood; D000818:Animals; D004140:Dinitrophenols / Q000494:pharmacology; D004734:Energy Metabolism; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008297:Male; D009573:Nitrites / Q000494:pharmacology*; D010084:Oxidation-Reduction; D010659:Phenylhydrazines / Q000494:pharmacology*; D011817:Rabbits; D012156:Reticulocytes / Q000187:drug effects / Q000378:metabolism*; D013816:Thermodynamics; D014452:Ubiquitins / Q000097:blood
D004140:Dinitrophenols; D006454:Hemoglobins; D009573:Nitrites; D010659:Phenylhydrazines; D014452:Ubiquitins; C030299:phenylhydrazine; D000255:Adenosine Triphosphate; D019297:2,4-Dinitrophenol